Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
AJANTPHARM
Mr. Yogesh Mannalal Agrawal M.B.A · Mumbai, India
₹3,396.50
▲+1.62%AJANTPHARM is rallying toward its 52-week high as investors reward a rare blend of high ROE (25.39%), strong revenue momentum (21.5% YoY), and ultra-low leverage (D/E 5.75%) in a sector where most peers trade at lower multiples.
Exchange
NSI
Currency
INR
Day range
₹3,325.20 – ₹3,414.00
52-week range
₹2,329.90 – ₹3,598.80
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis78% confidence
The stock trades in the upper third of its 52-week range at a forward P/E of ~40, which is a premium but defensible given that current price embeds a growth trajectory consistent with ROE above 25% and double-digit revenue growth — any pullback would likely be the more attractive entry, and the strong_buy consensus suggests upside from current levels outweighs near-term stretch.
5.6% below the 1-year high · trend up
Hedge-fund memo
Today
Up 1.62% on the day; trading close to the daily high of 3414, buying interest is confident with volume at ~103K on a stock of this size
This week
Trend has been positive with the stock climbing from the mid-range toward the 52-week high at 3598.8, with momentum intact
This month
The 52-week range of 2329.9–3598.8 indicates the stock has nearly retraced its entire prior decline, placing it in a technically strong posture
Bull thesis
Bear thesis
News & sentiment
Bullish
2 headlines · 1 outlets · 7d
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 4 recent quarters (EPS actual vs. consensus).
21.34 vs 20.3375
4.93% surprise
21.91 vs 19.83667
10.45% surprise
20.82 vs 21.65
-3.83% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| AJANTPHARM | 424.34B | 40.17 | 25.39% | 23.19% | 21.50% |
| TORNTPHARM | 1.86T | 76.61 | 16.99% | 20.20% | 41.80% |
| APLLTD | 159.60B | 23.67 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory adverse event (USFDA/EU warning letter or import ban) in an export market
Mitigation: Diversifying formulation approvals across geographies; maintaining strong current good manufacturing practices (cGMP)
Valuation compression if broader pharma sector rotates out of high-P/E names
Mitigation: Hold only as part of a diversified pharma sleeve; avoid overconcentration
Rising input costs for APIs and excipients compressing margins
Mitigation: Vertical integration into API manufacturing and hedged raw-material contracts
Business intelligence
Competitive moat
A 25.39% ROE combined with 19.37% profit margins and consistent 21.5% revenue growth points to durable pricing power and operational efficiency that most domestic generic peers cannot replicate at scale.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
No notable recent activity flagged.
Catalyst calendar
Potential USFDA approvals for new formulation exports
Quarterly results that could confirm or challenge the 21.5% revenue growth trajectory
New therapeutic launches in the specialty & generic pipeline
Generic patent expiries in key export markets creating opportunity for volume ramp
Thesis builder
Bull case
Continued export-led revenue growth, margin durability, and new therapeutic launches drive re-rating above current levels toward the 52-week high and beyond, as low debt enables aggressive capacity investment.
Base case
Steady 18-22% revenue expansion, stable to slightly expanding margins, and continued strong_buy analyst consensus sustain the stock in the upper range of a 3200–3600 trading band.
Bear case
A missed earnings print or USFDA adverse outcome compresses valuation from a ~40 P/E toward the pharma sector average of 25-30, testing the 52-week low of 2329.9 as a potential support level.
Time horizon
12–24 months for thesis to fully unfold; near-term is a risk-reward trade given rich valuation
Est. CAGR
~15–20% revenue CAGR over 3–5 years if export trajectory holds
Entry (qual.)
The stock at 3396.5 is rich — limit orders toward the 3200–3300 zone would improve risk/reward; incremental accumulation only on pullbacks
Exit (qual.)
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how AJANTPHARM fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain AJANTPHARM for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
Position as a core healthcare holding for growth-oriented portfolios, but size cautiously given the premium valuation and the stock trading near its 52-week high.
TradingView·7h ago·branded and US generics drove growth
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
20.43 vs 20.9
-2.25% surprise
| 12.36% |
| 7.39% |
| 4.40% |
| ALKEM | 678.23B | 29.43 | 17.56% | 11.42% | 14.60% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹3,325.20
Resistance (day/52w high)
₹3,414.00
Volume
1,03,603
Trend
up
RSI (14)
57
MACD
bearish
MA cross
golden
50-day MA
₹3,212.38
200-day MA
₹2,883.64
vs 200-DMA
17.8%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Trim a partial position if the stock breaches the 52-week high of 3598.8 on low volume, or exit entirely on a back-half EPS cut or regulatory adverse event
Overall conviction 78%